Meridian Bioscience Inc. [NASDAQ:VIVO] is seeing significant action in the Healthcare space. VIVO stock has price per sales of 2.65 and price per cash flow of 17.68. The company is also booking 1.02 earnings per share.
The tape is active for Meridian Bioscience Inc. [VIVO] and the current price target sits at $27.33.
To add more color to this price target, VIVO’s high over the last year is $34.00 and the low is $24.00. Over the last two 52 weeks, the company is trading 58.49%, while the S&P 500 is trading 0.17%.
The Bears are coming
Holding a Market Cap of $636.54 million, Meridian Bioscience Inc. has seen a trading range over the last year of $5.51-$26.58.
For the last five days, VIVO is down from its last closing price. The average shares trading hands each day is 733.96K, with average 10-day volume coming in at 0.57 million.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for VIVO. When we apply the Elder Force Index to Meridian Bioscience Inc., we are seeing an Elder Force Indicator number of -1619656.5.
The recent performance of the stock is another area that can tell traders how to proceed. VIVO is presenting an interesting case. This can be seen in the Forward P/E ratio, which currently stands at 14.40. Moreover, the company’s enterprise value has gone from $1.00B to $372.86M quarter-over-quarter. Obviously, the company is heading in the wrong direction, but there are still opportunities for growth in the sector.
In the last quarter, VIVO made a profit of 55.85 million. Meridian Bioscience Inc. also saw quarter revenue growth year over year of -5.88%. In addition, the company has operating cash flow of $38.99 million.
Looking at popular technical indicators, the company’s 5-day moving average is 15.83 compared to the 50-day moving average of 21.69. So, traders might want to tread carefully if they are going to bid.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. VIVO currently holds a 9-day RSI of 18.23%, while 100-day RSI stands at 49.35%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. VIVO’s 9-day MACD is -1.12 and the company’s 100-day MACD stands at -2.21.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 1.17% by insiders and 87.16% by institutions. Regarding institutional holdings, Blackrock Inc. owns 15.54%, while the second top holder, Vanguard Group, Inc. (The), currently owns 10.64%.
Over the last six months, insiders have bought 1,550 with the most recent transaction from Williams Felicia, Director, with a purchase at price 6.02 per share.
Overall, the recommended rating for VIVO is Strong Buy. Currently, the company has 4 analysts watching the stock, and the average quarterly earnings estimate is 0.15. Quarterly revenue estimates are averaging 59.64M with the high estimate reaching 60.21M and the low at 59.15M.
To review, the current 1-year target estimate is sitting at 27.33, while the current price 14.66. Based on this, we expect the stock to rise considering the aforementioned fundamentals.